CA Patent

CA2725930A1 — Methods for treating visceral fat conditions

Assigned to Orexigen Therapeutics Inc · Expires 2009-12-30 · 16y expired

What this patent protects

Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion.

USPTO Abstract

Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion.

Drugs covered by this patent

Patent Metadata

Patent number: CA2725930A1
Jurisdiction: CA
Classification: —
Expires: 2009-12-30
Drug substance claim: No
Drug product claim: No
Assignee: Orexigen Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.